0.0100CAD0.00%Mkt Cap: 540000 CADP/E: —Last update: 2026-05-29
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer tr…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap540.00K CAD
Enterprise Value4.01M CAD
Revenue (TTM)1.25M CAD
Gross Profit513.68K CAD
Net Income (TTM)-499.21K CAD
Revenue/Share0.0230 CAD
Last Price0.0100 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-10.83
EV/Revenue3.22
P/S0.43
P/B-0.23
EPS (TTM)-0.01
EPS (Forward)—
52W Range
0.01000% of range0.0400
52W High0.0400 CAD
52W Low0.0100 CAD
Profitability
Gross Margin38.06%
Oper. Margin-42.78%
EBITDA Margin-29.73%
Profit Margin-36.99%
ROE19.42%
ROA-40.12%
Growth
Revenue Growth-26.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-611.03K CAD
CapEx (TTM)—
FCF Margin-31.37%
FCF Yield-72.35%
Net Debt3.47M CAD
Net Debt/EBITDA-9.38
Balance Sheet
Debt/Equity-1.34
Current Ratio0.11
Quick Ratio0.02
Book Value/Sh-0.0440 CAD
Cash/Share0.0010 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.54.00M
Float13.55M
Insiders74.90%
Institutions0.00%
Short Interest
Short Ratio0.0d
Short % Out.0.00%
Shares Short571
Short (prev mo.)988
Technical
SMA 500.0121 (-17.4%)
SMA 2000.0175 (-42.9%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)733
Avg Vol (10d)200
Technical Indicators
RSI (14)25.2
MACD-0.0006
MACD Signal-0.0008
MACD Hist.+0.0002
BB Upper0.0100 CAD
BB Middle0.0100 CAD
BB Lower0.0100 CAD
BB Width0.00%
ATR (14)0.0002 CAD
Vol Ratio (20d)—